|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| The contraceptive use of depot medroxyprogesterone acetate. |
| CLINICAL OBSTETRICS AND GYNECOLOGY. 1995 Dec;38(4):849-58. |
| Depot medroxyprogesterone acetate (DMPA) was the first popular long-acting progestogen-only contraceptive, and is |
| used by more than nine million women worldwide. It is one of the most convenient and effective, yet readily |
| reversible methods of contraception. Although application was first submitted to the US Food and Drug |
| Administration in 1967 for approval to market DMPA as a contraceptive, final approval only came years later in late |
| 1992. DMPA is now approved for marketing as a contraceptive in more than 100 countries, mainly as Depo-Provera |
| for intramuscular use in a 150 mg dose, although several generic products are available in many countries. Many |
| clinicians have access to DMPA as a contraceptive for the first time, and most are aware of the substantial |
| controversy surrounding its use. This paper discusses the role of DMPA in the current array of contraceptive |
| choices, offering guidance for the common clinical problems which may present with use. Sections cover dosage, |
| administration, and contraceptive action; advantages and disadvantages of DMPA; controversies and DMPA; |
| acceptability; and indications and contraindications for use (PubHealth.info Document ID: CONT2T 2506-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "The contraceptive use of depot medroxyprogesterone |
| acetate.", is(are) Hickey M; Fraser I. The source of this article is "CLINICAL OBSTETRICS AND GYNECOLOGY. |
| 1995 Dec;38(4):849-58.". This article was published in 1995 in English language(s). (PubHealth.info® Document ID: |
| CONT2T 2506-06. All rights reserved with PubHealth.info) PIN: 7506 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |